A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction
brief summary
The main purpose of this study is to demonstrate the superiority of pacibekitug compared to placebo in reducing the risk of 3-point coronary major adverse cardiovascular events (3P-Coronary- MACE), defined as a composite of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), and urgent coronary revascularization, in participants after an MI, at high cardiovascular (CV) risk and receiving standard of care (SoC) secondary CV prevention therapies.
detailed description
Randomized, double-blind, parallel group, placebo-controlled, multi-center, global, event-driven study evaluating pacibekitug compared to placebo.
The study will consist of an optional pre-screening period of up to \~ 15 days, a screening period of up to \~ 30 days, a double-blind treatment period and a safety follow-up call.
The study is event-driven and designed to complete when both criteria are met: (a) at least 860 participants have experienced a CEC-confirmed primary 3P-Coronary-MACE across both treatment arms, (b) at least 85% of participants have been followed for at least 1 year during the double-blind treatment period.
official title
A Randomized, Double-blind, Placebo-controlled, Multi-center Trial Assessing the Effect of Pacibekitug on Major Cardiovascular Events in Participants After a Myocardial Infarction and at High Cardiovascular Risk (PINNACLE-MI)